Skip to main content

Skin Inflammation & Psoriasis International Network (SPIN), 2025

Filter
Close
Content type:
Bimekizumab efficacy by patient subgroups in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT
Christopher J Sayed, Martina L. Porter, Kokolakis Georgios, et al.
Poster
Bimekizumab 2-year impact on HSSQ skin pain in moderate to severe HS: data from BE HEARD EXT
Lauren A.V. Orenstein, Vivian Y. Shi, Lev-Tov Hadar, et al.
Poster
Bimekizumab impact on draining tunnels over 2 years in HS: data from BE HEARD EXT
Christos C Zouboulis, Hsiao Jennifer, Amit Garg, et al.
Poster
Bimekizumab achievement of ‘super response’ using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials
Lebwohl Mark, Langley G. Richard, Strober Bruce, et al.
Poster
Normalisation of molecular signatures associated with pruritus in plaque psoriasis correlates with itch resolution following bimekizumab treatment
Cutcutache Ioana, Rastrick Joe, Ferecsko Alex, et al.
Poster
Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies
Richard B Warren, Diamant Thaçi, Armstrong April, et al.
Poster
Bimekizumab efficacy in high-impact areas for patients with moderate to severe plaque psoriasis: Percentage change from baseline through 4 years from BE BRIGHT
Joseph F. Merola, Vender Ronald, Elewski Boni, et al.
Poster
Sustained reduction in pain and fatigue with bimekizumab treatment in patients with active psoriatic arthritis over 3 years: Results from two phase 3 studies
Alice B Gottlieb, Passeron Thierry, Mitsumasa Kishimoto, et al.
Poster
Bimekizumab impact on pain and quality of life stratified by IHS4 levels in patients with hidradenitis suppurativa: 2-year results from BE HEARD EXT
Kirby Brian, Khattri Saakshi, Ingram R. John, et al.
Poster